



## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

To,  
The Listing Department,  
BSE Ltd.

November 13, 2019

### Sub: Outcome of Board Meeting held on November 13, 2019.

We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses:

1. Approved the un-audited standalone and consolidated financials for the half year ended September 30, 2019.
2. Took note of the Limited Review Reports received from the statutory auditors.

The un-audited financial results for the half year ended September 30, 2019 along with the limited review reports is enclosed herewith.

We hereby submit that there is no deviation or variation in use of proceeds of Preferential Issue from the objects as stated in the explanatory statement of Notice of EGM held on September 29, 2018.

Kindly refer notes to standalone and consolidated statements for category wise details of projected utilization and actual utilization of proceeds from preferential allotment. The said has also been taken note by the Audit Committee and the Board in their meeting held today.

The Board Meeting commenced at 2.30 P.M. and concluded at 8:00 P.M.

This for your information and dissemination to the public.

**For VANTA BIOSCIENCE LIMITED**  
**Scrip Code: 540729 I Scrip ID: VANTABIO**


**DOPESH RAJA MULAKALA**  
**Managing Director**  
**DIN: 01176660**



**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Limited Review Report on unaudited standalone half yearly and year to date financial results of the Company**

**To The Board of Directors of  
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Standalone unaudited financial results of Vanta Bioscience Limited ("the Company") for the half year ended on 30<sup>th</sup> September, 2019 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

  
**B. V. RAMANA REDDY**  
M. No: 026967 Partner



**UIDN: 19026967AAAAEV5618**

Place: Hyderabad  
Date: 13.11.2019

E-mail : [mateshca@yahoo.co.in](mailto:mateshca@yahoo.co.in)



**MATHESH & RAMANA**  
**CHARTERED ACCOUNTANTS**


**Independent Auditor's Limited Review Report on unaudited consolidated half yearly  
and year to date financial results of the Company**

**To The Board of Directors of  
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Vanta Bioscience Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred as "the Group") for the half year ended on 30<sup>th</sup> September, 2019 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Vanta Bioscience Limited- Parent Company
  - b. Vanta Clinical Research Limited- Subsidiary Company
  - c. Vayam Research Solutions Limited-Step Down Subsidiary



E-mail : [matheshca@yahoo.co.in](mailto:matheshca@yahoo.co.in)




**MATHESH & RAMANA**  
**CHARTERED ACCOUNTANTS**

5. Based on our review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements/ financial information/ financial results of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total assets of Rs.4388.19 Lakhs as at September 30, 2019 and total revenues of Rs.733.07 Lakhs for the half year ended September 30, 2019, total net profit after tax of Rs. 54.29 Lakhs and total comprehensive profit for the half year ended 30th September, 2019 and cash flows (net outflow) of Rs.314.06 Lakhs for the period from 1<sup>st</sup> April, 2019 to 30<sup>th</sup> September, 2019, as considered in the consolidated unaudited financial results.

These interim financial statements/ financial information/ financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

  
B. V. RAMANA REDDY  
M. No: 026967 Partner



**UIDN: 19026967AAAAEW7554**

Place: Hyderabad  
Date: 13.11.2019

F-mail : [mateshca@yahoo.co.in](mailto:mateshca@yahoo.co.in)

# 3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863



# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED									
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003									
CIN L74999TG2016PLC109280									
STATEMENT OF STANDALONE & CONSOLIDATED AUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2019									
		STANDALONE				CONSOLIDATED			
		Half Year Ended		Year Ended		Half Year Ended		Year Ended	
		30.09.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (Audited)	31.03.2019 (Audited)	30.09.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (Audited)	31.03.2019 (Audited)
1	<b>Income</b>								
	Revenue from Operation	730.07	602.22	640.26	1242.48	733.07	602.22	646.06	1248.28
	Other Income	-	7.56	15.32	22.88	0	7.56	15.40	22.96
	<b>Total Revenue</b>	<b>730.07</b>	<b>609.78</b>	<b>655.58</b>	<b>1265.36</b>	<b>733.07</b>	<b>609.78</b>	<b>661.46</b>	<b>1271.24</b>
2	<b>Expenses</b>								
	a) Cost of material Consumed	81.46	75.89	63.91	139.80	81.46	75.89	63.91	139.80
	b) Employee Benfit Expenses	237.20	181.38	234.01	415.39	252.54	181.38	234.01	415.39
	c) Financial Cost	97.28	79.32	89.53	168.85	97.28	79.32	89.57	168.89
	d) Depreciation and amortization Exp	40.75	36.29	34.80	71.09	40.75	36.29	34.80	71.09
	e) other expenses	194.63	191.07	169.40	360.47	181.41	191.07	174.87	365.94
	<b>Total Expenses</b>	<b>651.32</b>	<b>563.95</b>	<b>591.65</b>	<b>1155.60</b>	<b>653.44</b>	<b>563.95</b>	<b>597.16</b>	<b>1161.11</b>
	<b>Profit/(Loss) from ordinary activities before</b>								
3	<b>Exceptional Items (1-2)</b>	<b>78.75</b>	<b>45.83</b>	<b>63.93</b>	<b>109.76</b>	<b>79.63</b>	<b>45.83</b>	<b>64.30</b>	<b>110.13</b>
4	Exceptional Items Income /(Expenses)	0	0	0	0	0	0	0	0
5	<b>Profit/(Loss) from ordinary activities before tax (3+4)</b>	<b>78.75</b>	<b>45.83</b>	<b>63.93</b>	<b>109.76</b>	<b>79.63</b>	<b>45.83</b>	<b>64.30</b>	<b>110.13</b>
6	<b>Tax Expenses</b>								
	a) Current Tax	15.17	8.82	14.07	22.89	19.14	8.82	14.16	22.98
	b) Deferred Tax	6.09	7.71	9.78	17.49	6.09	7.71	9.78	17.49
7	<b>Net Profit/(Loss) from ordinary activities after tax (5-6)</b>	<b>57.49</b>	<b>29.30</b>	<b>40.08</b>	<b>69.38</b>	<b>54.40</b>	<b>29.30</b>	<b>40.36</b>	<b>69.66</b>
8	Other Comprehensive Income / (expenses) for the year, net of tax	0	0	0	0	0	0	0	0
9	<b>Total Comprehensive Income/(Loss) Net of Tax (6+8)</b>	<b>57.49</b>	<b>29.30</b>	<b>40.08</b>	<b>69.38</b>	<b>54.40</b>	<b>29.30</b>	<b>40.36</b>	<b>69.66</b>
10	Paid up Equity share capital (face value of Rs.10/-)	631.20	572.80	631.20	631.20	631.20	572.80	631.20	631.20
11	Reserve excluding Revaluation reserve								
12	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)								
	a) Basic (Rs.)	0.91	0.51	0.77	1.17	0.86	0.51	0.78	1.19
	b) Diluted (Rs.)	0.91	0.51	0.77	1.17	0.86	0.51	0.78	1.19
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)								
	a) Basic (Rs.)	0.91	0.51	0.77	1.17	0.86	0.51	0.78	0.11
	b) Diluted (Rs.)	0.91	0.51	0.77	1.17	0.86	0.51	0.78	0.11
13	Debt Equity Ratio								
14	Debt Service Coverage Ratio (DSCR)								
15	Interest Service Coverage Ratio (DSCR)								

Place : Hyderabad  
Date : 13.11.2019





# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
 Rasoolpura, Secunderabad - 500 003, INDIA.  
 Tel : +91 40 6657 5454, 2790 3226  
 Fax : +91 40 2790 8708  
 Website : www.vantabio.com  
 Email : info@vantabio.com  
 CIN No. : L74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED					
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003					
CIN L74999TG2016PLC109280					
STATEMENT OF ASSETS & LIABILITIES AS ON 30th SEPTEMBER 2019					
Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		30.09.2019	31.03.2019	30.09.2019	31.03.2019
		Un-Audited	Audited	Un-Audited	Audited
A	<b>Equity and Liabilities</b>				
1	<b>EQUITY</b>				
	a) Equity share capital	631.20	631.20	631.20	631.20
	b) Reserve & Surplus	1650.80	1593.30	1647.87	1593.57
	c) Non Controlling/Minority Interest	0.00	0.00	98.24	0.00
	<b>Sub total Equity</b>	<b>2282.00</b>	<b>2224.50</b>	<b>2377.31</b>	<b>2224.77</b>
	<b>LIABILITIES</b>				
2	<b>Non Current Liabilities</b>				
	a) Financial Liabilities				
	i) Borrowings	1147.92	1216.63	1147.92	1266.61
	b) Provisions	0.00	0.00	0.00	0.00
	c) Deferred tax Liabilities	46.35	40.26	46.35	40.26
	d) Other Non Current Liabilities	0.00	0.00	0.00	3.54
	<b>Sub Total -Non Current Liabilities</b>	<b>1194.27</b>	<b>1256.89</b>	<b>1194.27</b>	<b>1310.41</b>
3	<b>Current Liabilities</b>				
	a) Financial Liabilities				
	i) Borrowings	165.06	0.00	165.06	0.00
	ii) Trade Payables	67.50	45.73	67.50	45.73
	b) Other Current Liabilities	282.71	260.99	557.23	260.99
	c) Provisions	22.70	12.17	26.82	14.32
	d) Current tax Liabilities(net)	0.00	0.00	0.00	0.00
	<b>Sub Total -Non Current Liabilities</b>	<b>537.97</b>	<b>318.89</b>	<b>816.61</b>	<b>321.04</b>
	<b>Total Equity and Liabilities</b>	<b>4014.24</b>	<b>3800.28</b>	<b>4388.19</b>	<b>3856.23</b>
B	<b>ASSETS</b>				
1	<b>Non Current Assets</b>				
	a) Property, Plant and Equipment	1667.01	1303.75	1667.01	1303.75
	b) Capital Work in Progress	0.00	369.84	525.34	369.84
	c) Other Intangible assets	486.23	486.23	486.23	486.23
	d) Other Intangible assets under development	0.00	0.00	0.00	0.00
	e) Investment in associates and joint ventures	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	200.00	199.99	0.00	0.00
	ii) Loans	0.00	0.00	0.00	98.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	35.04	35.04	96.76	35.04
	<b>Sub Total Non-CurrentAssets</b>	<b>2388.28</b>	<b>2394.85</b>	<b>2775.34</b>	<b>2292.86</b>
2	<b>Current Assets</b>				
	a) Inventories	1169.28	924.42	1169.28	924.42
	<b>b) Financial Assets</b>				
	i) Investments	5.00	195.00	5.00	195.00
	ii) Trade Receivable	232.46	156.40	235.46	161.56
	iii) Bank, Cash and Cash equivalents	9.72	28.43	12.57	180.55
	iv) Loans & Advances	197.08	89.62	178.12	90.04
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	12.42	11.56	12.42	11.79
	<b>Sub Total Current Assets</b>	<b>1625.96</b>	<b>1405.43</b>	<b>1612.85</b>	<b>1563.37</b>
	<b>Total Assets</b>	<b>4014.24</b>	<b>3800.28</b>	<b>4388.19</b>	<b>3856.23</b>

For and on behalf of Board of Directors

*M. D. Raju*

Place : Hyderabad  
 Date : 13.11.2019

Dopesh Raja Mulakala  
 Managing Director  
 DIN:01176660



Research Center  
 K12, 11th Cross Street, SIPCOT Indl. Complex  
 Gummidipundi, Thiruvallur District, Tamilnadu,  
 India 601 201. Tel : +91 44 6791 0300



# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
 Rasoolpura, Secunderabad - 500 003, INDIA.  
 Tel : +91 40 6657 5454, 2790 3226  
 Fax : +91 40 2790 8708  
 Website : www.vantabio.com  
 Email : info@vantabio.com  
 CIN No. : L74999TG2016PLC109280

<b>VANTA BIOSCIENCE LIMITED</b>				
Cash Flow statement for the period ended 30th September 2019				
Particulars	STANDALONE		CONSOLIDATED	
	For the period 30.09.2019	For the Year Ended 31.03.2019	For the period 30.09.2019	For the Year Ended 31.03.2019
<b>A. Cash Flow from Operating Activities</b>				
Profit before exceptional , Extraordinary items and Tax	78.75	109.76	79.63	110
<b>Adjustment for:</b>				
Depreciation	40.75	71.10	40.75	71
Finance Charges	97.28	168.85	97.28	169
Gain/Loss on foreign Exchange fluctuation	0.00	0.00	0.00	0.00
<b>Sub total</b>	<b>138.03</b>	<b>239.95</b>	<b>138.03</b>	<b>239.95</b>
<b>Operating profit Before Working Capital Changes</b>	<b>216.78</b>	<b>349.71</b>	<b>217.66</b>	<b>350.27</b>
<b>Adjustment for:</b>				
(Increase) /Decrease in Inventories	(244.86)	(621.98)	(244.86)	(621.98)
(Increase) /Decrease in Trade receivables	(76.07)	(123.38)	(79.07)	(130.48)
Increase /(Decrease) in trade payable	54.00	132.15	21.76	139.92
(Increase) /Decrease Loans & Advances	(108.31)	2.35	(86.94)	(96.53)
(Increase) /Decrease in Current Investment	190.00	255.00	190.00	255.00
(Increase) /Decrease in other Current Asset			(0.85)	0.00
(Increase) /Decrease in other Non Current Asset			(61.72)	0.00
(Increase) /Decrease in other Current Liabilities			309.53	0.00
<b>Sub total</b>	<b>(185.24)</b>	<b>(355.86)</b>	<b>47.85</b>	<b>(454.07)</b>
<b>Cash Generated from operations</b>	<b>31.54</b>	<b>(6.15)</b>	<b>265.51</b>	<b>(103.80)</b>
<b>Net Cash Flow from Operating Activities</b>	<b>31.54</b>	<b>(6.15)</b>	<b>265.51</b>	<b>(103.80)</b>
<b>B: Cash Flow from Investing Activities</b>				
Purchase of Fixed Assets	(34.17)	(247.58)	(34.17)	(247.58)
Capital Work In progress		0.00	(525.34)	0.00
proceeds from sale of Fixed Assets		0.00	0.00	0.00
Investment in Subsidiaries	0.00	(200.00)	0.00	(302.00)
<b>Net Cash Flow from Investing Activities</b>	<b>(34.17)</b>	<b>(447.58)</b>	<b>(559.51)</b>	<b>(549.58)</b>
<b>C: Cash Flow from Financing Activities</b>				
Increase /(Decrease) in Unsecured Loan			0.00	98.00
Increase /(Decrease) in Working capital	165.06	(49.85)	165.06	(49.85)
Increase /(Decrease) in Term Loan	(68.70)	218.62	(68.70)	218.62
Increase /(Decrease) in share capital	0.00	58.40	0.00	458.40
Increase /(Decrease) in share Premium	0.00	438.00	0.00	438.00
Finance Charges	(97.28)	(168.85)	(97.28)	(168.85)
<b>Net Cash Flow from Financing Activities</b>	<b>(0.92)</b>	<b>496.32</b>	<b>(0.92)</b>	<b>994.32</b>
Actual Payment of Income Tax	(15.16)	(22.89)	(19.14)	(23.04)
<b>D: Net Increase/Decrease in Cash and cash Equivalents</b>	<b>(18.71)</b>	<b>19.70</b>	<b>(314.06)</b>	<b>317.90</b>
<b>Opening of Cash &amp; Cash Equivalents</b>	<b>28.43</b>	<b>8.73</b>	<b>326.63</b>	<b>8.73</b>
<b>Closing Balance of Cash &amp; Cash Equivalents</b>	<b>9.72</b>	<b>28.43</b>	<b>12.57</b>	<b>326.63</b>
See accompanying notes to the financial statements As per our report of even date annexed.				

For and on behalf of Board of Directors

*(Signature)*  
 Dopesh Raja Mulakala  
 Managing Director

Research Center  
 CIN: L74999TG2016PLC109280





## Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : L74999TG2016PLC109280

### Notes to Standalone and consolidated financial statements:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13<sup>th</sup> November, 2019.
2. As per MCA Notification dated 16<sup>th</sup> February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
3. Statement of Assets and Liabilities as on 30<sup>th</sup> September 2019 is enclosed herewith.
4. Statement of Cash flow for half year ended 30<sup>th</sup> September 2019 is enclosed herewith.
5. There were no investor complaints received/pending as at 30<sup>th</sup> September, 2019.
6. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.

The Company during the previous year issued 5,84,000 equity shares of Rs. 10/- each at a premium of Rs. 75/— on preferential basis and their utilization is as follows:

(Amount In Rs Lakhs)

<b>Proceeds from Preferential Allotment</b>	<b>496.40</b>
<b>Utilization</b>	
Investment/ Loans in Subsidiary	343.00
General Corporate and Working Capital	123.40
Issue Expense	25.00
Balance- Investment in Liquid funds	5.00
<b>Total</b>	<b>496.40</b>

8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
9. The said results are uploaded on the website of the Company www.vantabio.com and on BSE Ltd.

